More importantly, ruxolitinib treatment rescues splenomegaly and lymphadenopathy observed in C9orf72−/− mice (Figure 5), confirming the importance of the JAK-STAT activation in the inflammatory responses under C9ORF72 deficient conditions. This evidence concerns the gene SOAT1 and Splenomegaly.